TorreyPines Therapeutics initiated a Phase I trial for NGX426, an oral therapy intended to treat migraine and chronic pain conditions such as neuropathic pain. The double-blind, placebo-controlled, single ascending dose study, will evaluate the safety, tolerability and pharmacokinetics of NGX426 in 30 healthy volunteers. NGX426 is a prodrug of tezampanel, the company’s parenteral product candidate in development for migraine. Tezampanel and NGX426 are AK receptor antagonists that poten...